Related Experiment Video

Updated: Mar 22, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based

I Campos-Varela1,2,3, A Moreno4, A Morbey5

  • 1Universidade de Santiago de Compostela (CLINURSID), Santiago de Compostela, Spain.

Alimentary Pharmacology & Therapeutics
|April 22, 2016
PubMed

Insights

Sofosbuvir-based therapy effectively treated hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection in liver transplant recipients. This treatment achieved high sustained virological response (SVR) rates with good safety and tolerability.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection in liver transplant recipients (LT) increases graft loss risk.
  • Previous HCV treatments had significant side effects and drug-drug interactions.

Purpose of the Study:

  • To assess the effectiveness and safety of sofosbuvir (SOF)-based therapy for HIV/HCV co-infected liver transplant recipients.
  • To evaluate treatment outcomes in a compassionate access program.

Main Methods:

  • Twenty liver transplant recipients with HIV/HCV co-infection were treated with SOF-based regimens.
  • Treatment regimens included SOF with ribavirin (RBV), Peg-interferon, or simeprevir, and daclatasvir.
  • Outcomes were assessed for patients with severe recurrence or cirrhosis.

Main Results:

  • 16 out of 18 (89%) patients achieved sustained virological response 12 weeks post-treatment (SVR12).
  • Liver function tests significantly improved; no compromise in HIV suppression or significant drug-drug interactions were reported.
  • Serious adverse events occurred in 40% of patients, none attributed to SOF.

Conclusions:

  • Sofosbuvir-based regimens are safe and well-tolerated in liver transplant recipients with HIV/HCV co-infection.
  • These regimens achieve high SVR rates in patients with severe recurrence post-liver transplant.
  • Treatment demonstrated efficacy without negatively impacting HIV management.
Abstract

More Related Videos

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

9.2K
Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

8.6K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
27
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
4
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
613
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K